Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NVCT stock hub

Nuvectis Pharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NVCTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

309M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NVCT

In the news

Latest news · NVCT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-154.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-100.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NVCT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

164

Groups with data

Currency

USD

Showing 164 of 164 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001875558
Company name	Nuvectis Pharma, Inc.
Country	United States
Country code	US
Cusip	67080T108
Employees	13
Employees Change	2%
Employees Change Percent	18.18
Enterprise value	$283.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2022-02-04
Isin	US67080T1088
Last refreshed	2026-05-10
Market cap	$309M
Market cap category	Small-Cap
Price	$11.65
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	NVCT
Website	https://www.nuvectis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-9.58%
P/B ratio	21.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-29.6M
Net Income Growth Years	0%
Profit Per Employee	$-2.3M
ROA	-63.61
ROCE	-198.8
ROE	-154.4
Roe5y	-269.3
ROIC	-100.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	33.02%
Cagr3y	-8.18%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$25.4M
Cash	$25.1M
Current Assets	$25.4M
Current Liabilities	$11.2M
Equity	$14.2M
Liabilities	$11.2M
Long Term Assets	$0
Long Term Liabilities	$0
Net Cash	$25.1M
Net Cash By Market Cap	$8.13
Net Cash Growth	-15.85%
Net Debt Equity	$-1.77
Tangible Book Value	$14.2M
Tangible Book Value Per Share	$0.54
WACC	3.61

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.27
Net Working Capital	$-10.9M
Quick ratio	2.25
Working Capital	$14.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-26.31%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	32.99%
200-day SMA	7.44
3Y total return	-22.59%
50-day SMA	8.64
50-day SMA vs 200-day SMA	50over200
All Time High	20.92
All Time High Change	-44.31%
All Time High Date	2022-05-18
All Time Low	3.08
All Time Low Change	278.25%
All Time Low Date	2022-02-04
ATR	0.54
Beta	-0.12
Beta1y	0.75
Beta2y	1.77
Ch YTD	54.31
High	11.74
High52	11.74
High52 Date	2026-05-08
High52ch	-0.77%
Low	10.07
Low52	5.55
Low52 Date	2025-11-07
Low52ch	109.91%
Ma50ch	34.87%
Premarket Change Percent	-5.64
Premarket Price	$9.74
Premarket Volume	251
Price vs 200-day SMA	56.52%
RSI	81.87
RSI Monthly	62.35
RSI Weekly	71.75
Sharpe ratio	0.71x
Sortino ratio	1.27
Total Return	-26.31%
Tr YTD	54.31
Tr1m	46.91%
Tr1w	36.42%
Tr3m	31.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.31
Operating Income	$-28.3M
Price target	$10
Price Target Change	$-14.16

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	15,472,745%
Float Percent	58.33%
Shares Insiders	41.67%
Shares Institutions	17.44%
Shares Out	26,525,533
Shares Qo Q	0.94%
Shares Yo Y	26.31%
Short Float	9.96%
Short Ratio	25.52
Short Shares	5.81

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	71,277.5x
Bv Per Share	0.54
Ch1m	46.91
Ch1w	36.42
Ch1y	32.99
Ch3m	31.05
Ch3y	-22.59
Ch6m	89.74
Change	12.89%
Change From Open	12.89
Close	10.32
Days Gap	0
Dollar Volume	2,125,810.5
Earnings Date	2026-05-05
Earnings Time	bmo
EBIT	$-28.3M
EPS	$-1.3
F Score	1
Financing CF	13,612,000
Fiscal Year End	December
Founded	2,020
Ipr	133
Iprfo	194.9
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Ma150	7.75
Ma150ch	50.28%
Ma20	9
Ma20ch	29.46%
Net CF	-4,734,000
Next Earnings Date	2026-08-04
Open	10.32
Optionable	Yes
Position In Range	94.61
Post Close	11.65
Postmarket Change Percent	-3.43
Postmarket Price	$11.25
Pre Close	10.32
Price Date	2026-05-08
Ptbv Ratio	21.73
Relative Volume	2.56x
Share Based Comp	6,514,000
Tr6m	89.74%
Us State	New Jersey
Volume	182,473

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NVCT pay a dividend?

Capital-return profile for this ticker.

Performance

NVCT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NVCT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.4%

Float: +58.3% of shares outstanding

Insider ownership

+41.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NVCT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

81.9

Above 70: short-term overbought

Price vs 200-day MA

+56.5%

50/200-day relationship not available

Beta (5Y)

-0.12

Less volatile than the market

Sharpe ratio

0.71

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NVCT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NVCT stock rating?

Nuvectis Pharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NVCT analysis?

The full report lives at /stocks/NVCT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NVCT?

The latest report frames NVCT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NVCT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.